Literature DB >> 23203409

Antagonistic effect of C19 on migration of vascular smooth muscle cells and intimal hyperplasia induced by chemokine-like factor 1.

Tao Zhang1, Zhengguo Qiao, Feng Chen, Xiaoming Zhang, Jiang Xiong, Xin Jia, Jian Chen, Chenyang Shen, Wei Guo.   

Abstract

A chemokine-like factor 1 (CKLF1) is a recently discovered chemokine with broad-spectrum biological functions in inflammation and autoimmune diseases. C19 as a CKLF1's C-terminal peptide has been reported to exert inhibitory effects in a variety of diseases. However, the roles of CKLF1 and C19 on vascular smooth muscle cell (VSMC) migration and neointima formation still remain elusive. The effects of CKLF1 and C19 on VSMC migration and neointimal formation were investigated in cultured VSMCs and balloon-injured rat carotid arteries based on techniques including adenovirus-induced CKLF1 overexpression, gel based perivascular administration of C19, Boyden chamber, scratch-wound assay, real-time PCR, western blot and immunohistochemical analysis. CKLF1 was noticed to accumulate preferentially in neointima after the injury and colocalize with VSMCs. Luminal delivery of CKLF1 adenovirus to arteries exacerbated intimal thickening while perivascular administration of C19 to injured arteries attenuated this problem. In cultured primary VSMCs, CKLF1 overexpression up-regulated VSMC migration, which was down-regulated by C19. These data suggest that CKLF1 has a pivotal role in intimal hyperplasia by mediating VSMC migration. C19 was demonstrated to inhibit CKLF1-mediatated chemotaxis and restenosis. Thus further studies on C19 may provide a new treatment perspective for atherosclerosis and post-angioplasty restenosis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23203409     DOI: 10.1007/s11033-012-2309-1

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  25 in total

Review 1.  Mechanisms of vascular smooth muscle cell migration.

Authors:  William T Gerthoffer
Journal:  Circ Res       Date:  2007-03-16       Impact factor: 17.367

Review 2.  An introductory review of cell mechanobiology.

Authors:  J H-C Wang; B P Thampatty
Journal:  Biomech Model Mechanobiol       Date:  2006-01-28

3.  Effects of novel human chemokine-like factor 1 (CKLF1) on bone marrow hematopoietic stem cell/progenitor cell in vitro.

Authors:  Xiaoyan Ke; Liping Jia; Hongmei Jing; Yan Liu; Yingmei Zhang; Chunhui Di
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2002-06

4.  C19, a C-terminal peptide of chemokine-like factor 1, protects the brain against focal brain ischemia in rats.

Authors:  Ling-Lei Kong; Jin-Feng Hu; Wei Zhang; Yu-He Yuan; Ning Han; Nai-Hong Chen
Journal:  Neurosci Lett       Date:  2011-12-06       Impact factor: 3.046

Review 5.  Chemokines in vascular pathology (review).

Authors:  Stavros Apostolakis; Emmanouil G Papadakis; Elias Krambovitis; Demetrios A Spandidos
Journal:  Int J Mol Med       Date:  2006-05       Impact factor: 4.101

Review 6.  The pathophysiology and burden of restenosis.

Authors:  William S Weintraub
Journal:  Am J Cardiol       Date:  2007-06-26       Impact factor: 2.778

Review 7.  Molecular mechanisms of restenosis after percutaneous peripheral angioplasty and approach to endovascular therapy.

Authors:  Annalisa Mongiardo; Antonio Curcio; Carmen Spaccarotella; Simona Parise; Ciro Indolfi
Journal:  Curr Drug Targets Cardiovasc Haematol Disord       Date:  2004-09

8.  Two C-terminal peptides of human CKLF1 interact with the chemokine receptor CCR4.

Authors:  Ying Wang; Yingmei Zhang; Wenling Han; Dan Li; Linjie Tian; Caihua Yin; Dalong Ma
Journal:  Int J Biochem Cell Biol       Date:  2007-11-04       Impact factor: 5.085

Review 9.  Anti-chemokine therapy for inflammatory diseases.

Authors:  M L Castellani; K Bhattacharya; M Tagen; D Kempuraj; A Perrella; M De Lutiis; W Boucher; P Conti; T C Theoharides; G Cerulli; V Salini; G Neri
Journal:  Int J Immunopathol Pharmacol       Date:  2007 Jul-Sep       Impact factor: 3.219

10.  Chemokine-like factor 1, a novel cytokine, contributes to airway damage, remodeling and pulmonary fibrosis.

Authors:  Ya-xia Tan; Wen-ling Han; Ying-yu Chen; Neng-tai Ouyang; Yan Tang; Feng Li; Pei-guo Ding; Xiao-lan Ren; Guang-qiao Zeng; Jing Ding; Tong Zhu; Da-long Ma; Nan-shan Zhong
Journal:  Chin Med J (Engl)       Date:  2004-08       Impact factor: 2.628

View more
  3 in total

1.  Chemokine-like factor 1: A promising therapeutic target in human diseases.

Authors:  Xiaopeng Cai; Jingwen Deng; Qianqian Ming; Huiqiang Cai; Zhi Chen
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-26

2.  Chemokine-like factor 1-derived C-terminal peptides induce the proliferation of dermal microvascular endothelial cells in psoriasis.

Authors:  Yaqi Tan; Yixuan Wang; Li Li; Jinyu Xia; Shiguang Peng; Yanling He
Journal:  PLoS One       Date:  2015-04-27       Impact factor: 3.240

3.  C19, a C-terminal peptide of CKLF1, decreases inflammation and proliferation of dermal capillaries in psoriasis.

Authors:  Yi Zheng; Yixuan Wang; Xuan Zhang; Yaqi Tan; Shiguang Peng; Le Chen; Yanling He
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.